10.3389/fonc.2019.01066.s002
Xi Li
Xi
Li
Rouzheng Wang
Rouzheng
Wang
Peiwen Fan
Peiwen
Fan
Xuan Yao
Xuan
Yao
Ling Qin
Ling
Qin
Yanchun Peng
Yanchun
Peng
Miaomiao Ma
Miaomiao
Ma
Neil Asley
Neil
Asley
Xuimei Chang
Xuimei
Chang
Yaning Feng
Yaning
Feng
Yunhui Hu
Yunhui
Hu
Yonghong Zhang
Yonghong
Zhang
Chris Li
Chris
Li
Gregory Fanning
Gregory
Fanning
Stephanie Jones
Stephanie
Jones
Clare Verrill
Clare
Verrill
David Maldonado-Perez
David
Maldonado-Perez
Paul Sopp
Paul
Sopp
Craig Waugh
Craig
Waugh
Stephen Taylor
Stephen
Taylor
Simon Mcgowan
Simon
Mcgowan
Vincenzo Cerundolo
Vincenzo
Cerundolo
Christopher Conlon
Christopher
Conlon
Andrew McMichael
Andrew
McMichael
Shichun Lu
Shichun
Lu
Xiyan Wang
Xiyan
Wang
Ning Li
Ning
Li
Tao Dong
Tao
Dong
Table_1_A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.XLSX
Frontiers
2019
T cells
inhibitory receptor
tumor-infiltrating lymphocytes
tumor microenvironment
combinatorial checkpoint blockade
2019-10-25 10:53:13
Dataset
https://frontiersin.figshare.com/articles/dataset/Table_1_A_Comprehensive_Analysis_of_Key_Immune_Checkpoint_Receptors_on_Tumor-Infiltrating_T_Cells_From_Multiple_Types_of_Cancer_XLSX/10048460
<p>Background: Cancer patients often display dysfunctional antitumor T-cell responses. Because noteworthy benefits of immune checkpoint pathway blockade, such as programmed cell death protein 1 (PD-1) inhibitors, have been achieved in multiple advanced cancers, the next critical question is which mono-blockade or combinatorial blockade regimens may reinvigorate antitumor T-cell immunity in those cancer patients while limiting immune-related adverse effects.</p><p>Method: This study recruited, in total, 172 primary cancer patients (131 were blood-tumor-matched patients) who were treatment-naïve prior to the surgeries or biopsies covering the eight most prevalent types of cancer. With access to fresh surgical samples, this study simultaneously investigated the ex vivo expression level of eight known immune checkpoint receptors [PD-1, cytotoxic T-lymphocyte antigen-4 [CTLA-4], T-cell immunoglobulin and mucin-domain containing-3 [Tim-3], 2B4, killer cell lectin like receptor G1 [KLRG-1], TIGIT, B- and T-lymphocyte attenuator [BTLA], and CD160] on tumor-infiltrating T cells (TILs) and paired circulating T cells in blood from a 131-patient cohort.</p><p>Results: We found increased an expression of PD-1 and Tim-3 but a decreased expression of BTLA on TILs when compared with peripheral blood from multiple types of cancer. Moreover, our co-expression analysis of key immune checkpoint receptors delineates “shared” subsets as PD-1+Tim-3+TIGIT+2B4+KLRG-1–CTLA-4– and PD-1+TIGIT+2B4+Tim-3–KLRG-1–CTLA-4– from bulk CD8 TILs. Furthermore, we found that a higher frequency of advanced differentiation stage T cells (CD27–CCR7–CD45RA–) among the “shared” subset (PD-1+Tim-3+TIGIT+2B4+KLRG-1–CTLA-4–) in bulk CD8 TILs was associated with poorly differentiated cancer type in cervical cancer patients.</p><p>Conclusions: To our knowledge, our study is the first comprehensive analysis of key immune checkpoint receptors on T cells in treatment-naïve, primary cancer patients from the eight most prevalent types of cancer. These findings might provide useful information for future design of mono-blockade/combinatorial blockades and/or genetically modified T-cell immunotherapy.</p>